Month: October 2012

La Vanguardia publishes an opinion article on research, by the IDIBELL general manager

The newspaper La Vanguardia publishes on Sunday, October 7th, an opinion article written by the IDIBELL general manager, Emilià Pola, on the future of the research and development in the world and in Catalonia. Pola highlights that “every biomedical researcher makes possible a business of 400,000 euros per year, five times more than it costs”. …

La Vanguardia publishes an opinion article on research, by the IDIBELL general manager Read More »

Annual Report 2011

In 2011, IDIBELL have continued increasing its scientific output focused on improving the health of people. Our researchers have continued publishing in top international journals and participating in leading research projects. The annual report 2011 highlights the most important facts of the year at the centre. A new feature of this edition is the inclusion …

Annual Report 2011 Read More »

The MED12 oncogene, key in response to cancer drugs

The MED12 oncogene is essential in monitoring response to new cancer drugs, according to the study published in Cell and leaded by researchers at the IDIBELL and ICO in collaboration with researchers from the Netherlands Cancer Institute (NKI) in Amsterdam. This research, published in Cell, has shown that MED12 oncogene plays a key role in …

The MED12 oncogene, key in response to cancer drugs Read More »

Aging and epigenetics in “Divendres” (TV3)

New advances in anti-aging research attended the “Divendres” program on TV3 last October 3. After an introduction about aging and how our habits determined up to 90% of our life, the journalist Xavi Coral talked with Dr. Manel Esteller, director of the Cancer Epigenetics and Biology Program in the Bellvitge Biomedical Research Institute (IDIBELL), Professor …

Aging and epigenetics in “Divendres” (TV3) Read More »

Scroll to Top